ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Sunday, November 7, 2021

8:30AM-10:30AM: Abstract Number: 0644

Follow-up Scheduling Appears Essential for Success of Rheumatology High Blood Pressure Protocol Across Health Systems

Measures & Measurement of Healthcare Quality Poster (0623–0659)

8:30AM-10:30AM: Abstract Number: 0542

Functional Characterization of Glycoprotein Nonmetastatic Melanoma Protein B in Scleroderma Fibrosis

Systemic Sclerosis & Related Disorders – Basic Science Poster (0541–0559)

8:30AM-10:30AM: Abstract Number: 0592

Gender Modifies the Effect of Rheumatoid Arthritis on All-Cause Mortality

Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)

8:30AM-10:30AM: Abstract Number: 0884

Genetics of Longitudinal Disease Activity in Adults with Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)

8:30AM-10:30AM: Abstract Number: 0776

Genetics of Neonatal Lupus Erythematosus Risk and Specific Manifestations

Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)

8:30AM-10:30AM: Abstract Number: 0522

Genetics of Rheumatoid Arthritis Remission; HLA-SE Associated with Remission in Anti-CCP Positive Patients

Genetics, Genomics & Proteomics Poster (0517–0533)

8:30AM-10:30AM: Abstract Number: 0521

Genome-Wide DNA Methylation and Gene Expression Signatures in Classical Monocytes from African Ancestry Patients with Systemic Sclerosis

Genetics, Genomics & Proteomics Poster (0517–0533)

8:30AM-10:30AM: Abstract Number: 0694

Glucagon-like Peptide-1 Receptor Agonist Suppresses Muscle Fiber Necroptosis and Muscle Inflammation and Ameliorates Muscle Weakness in Experimental Polymyositis

Muscle Biology, Myositis & Myopathies Poster (0683–0722)

8:30AM-10:30AM: Abstract Number: 0742

Googling Rheumatic Diseases: Evaluating the Reliability of Information Found on the Internet

Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)

8:30AM-10:30AM: Abstract Number: 0682

Gout Management and Outcomes During the COVID-19 Pandemic in Late 2020-2021: A Cross-sectional Internet Survey

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)

8:30AM-10:30AM: Abstract Number: 0680

Gout Stigma: Investigating the Existence of Gout Stigma and Its Impact on Patient Perceptions and Treatment Decisions

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)

8:30AM-10:30AM: Abstract Number: 0880

Health Information Use by SLE Patients Pre and During COVID-19

SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)

8:30AM-10:30AM: Abstract Number: 0894

Help-seeking Behaviors and Treatment Preferences for Sleep Problems Among Persons with Lupus

SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)

8:30AM-10:30AM: Abstract Number: 0670

Hemochromatosis Is Associated with CPPD Through Iron’s Effect on Bone

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)

8:30AM-10:30AM: Abstract Number: 0780

High Adolescent Health Needs and Relationship to Disease in Patients with Childhood-Onset Systemic Lupus Erythematosus

Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].